RD13-02

DB27110InvestigationalCell transplant therapies

RD13-02 is a biologic drug. RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).

Mechanism: Pharmacologically active on T-cell antigen CD7
Curator reviewed
Code names: RD13-02 · RD13-02 cell

Resolves to

Targets

P09564CD7

What you can answer from here — as of June 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with RD13-02, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account